Research Grade Caplacizumab (DHC08501)

Catalog No.

DHC08501

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

VH-VH

Clonality

Monoclonal

Target

von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF

Concentration

1.6 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P04275

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

20mM citric acid, 6.2% sucrose, 0.01% Tween 80

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

ALX-0081, PMP12A2h1-linker AAA-PMP12A2h1, caplacizumab-yhdp, CAS: 915810-67-2

Clone ID

Caplacizumab

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 30625070

Caplacizumab: First Global Approval, PMID: 30298461

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 26863353

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura, PMID: 32095224

Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura, PMID: 32588878

Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment, PMID: 31359806

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP, PMID: 33150928

Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura, PMID: 31250841

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura, PMID: 33280030

Real-world experience with caplacizumab in the management of acute TTP, PMID: 33150355

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura, PMID: 32634236

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study, PMID: 31691462

Caplacizumab, PMID: 30933455

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP, PMID: 32634237

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura, PMID: 30977686

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura, PMID: 32876503

Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?, PMID: 33236389

Caplacizumab (Cablivi) for iTTP, PMID: 33429409

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura, PMID: 31118566

Caplacizumab: frequent local skin reactions, PMID: 32997190

Caplacizumab for relapsing thrombotic thrombocytopenic purpura, PMID: 31177334

Thrombotic thrombocytopenic purpura, PMID: 28416507

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 31042846

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 31042845

Caplacizumab for thrombotic thrombocytopenic purpura, PMID: 33664548

The Therapeutic Potential of Nanobodies, PMID: 31686399

Caplacizumab, PMID: 34251781

Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma, PMID: 32358818

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply, PMID: 31042847

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 31576256

Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura, PMID: 32738052

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab, PMID: 33195299

Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura, PMID: 32605495

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura, PMID: 32914526

Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial), PMID: 31318128

Pharmacoeconomic Review Report: Caplacizumab (Cablivi): (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) [Internet], PMID: 33570888

New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab, PMID: 32715723

Counting the cost of caplacizumab, PMID: 33599760

Antibodies to watch in 2019, PMID: 30516432

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 31269374

Correction to: Caplacizumab: First Global Approval, PMID: 30511322

Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis, PMID: 33223471

ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura, PMID: 32914582

Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male, PMID: 33285299

Clinical Review Report: Caplacizumab (Cablivi): (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) [Internet], PMID: 33600100

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura, PMID: 28445600

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab, PMID: 31894592

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, PMID: 27332911

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer, PMID: 31544819

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura, PMID: 34109052

Document Download

Research Grade Caplacizumab.pdf